• Amarantus reacquires three diagnostic tests biospectrumasia
    April 10, 2018
    Under the terms of the deal, Amarantus will cancel about $722,000 in liabilities, owed by Avant. Amarantus will issue to Avant 1 million shares of its common stock, and Avant will issue to Amarantus an additional 32 million shares of its common stock as a
PharmaSources Customer Service